Copyright
©The Author(s) 2024.
World J Gastrointest Oncol. Feb 15, 2024; 16(2): 475-492
Published online Feb 15, 2024. doi: 10.4251/wjgo.v16.i2.475
Published online Feb 15, 2024. doi: 10.4251/wjgo.v16.i2.475
Figure 3 Expression and prognosis value of B56ε in hepatocellular carcinoma.
A: Analysis of the B56ε expression difference between hepatocellular carcinoma (HCC) tissues and normal liver tissues in The Cancer Genome Atlas (TCGA); B: Pairwise difference comparison of B56ε expression level between HCC tissues and normal liver tissues in the TCGA database; C: TCGA combined with Genotype-Tissue Expression databases to analyze the expression of B56ε in HCC tissues and normal liver tissues; D: Gene Expression Profiling Interactive Analysis was utilized for analyzing the relationship between B56ε expression and HCC overall survival time; E: Expression of B56ε protein in normal liver tissue and HCC tissue by the Human Protein Atlas database. cP < 0.001. HCC: Hepatocellular carcinoma.
- Citation: Wu HM, Huang YY, Xu YQ, Xiang WL, Yang C, Liu RY, Li D, Guo XF, Zhang ZB, Bei CH, Tan SK, Zhu XN. Comprehensive analysis of the protein phosphatase 2A regulatory subunit B56ε in pan-cancer and its role and mechanism in hepatocellular carcinoma. World J Gastrointest Oncol 2024; 16(2): 475-492
- URL: https://www.wjgnet.com/1948-5204/full/v16/i2/475.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v16.i2.475